Protein Degradation

Of the proteins encoded by the human genome, approximately over 30,000 participate in biological functions. However, only a small fraction of these represent druggable targets. Exploring undruggable targets, a highly challenging scientific puzzle in drug discovery, has garnered widespread attention. Emerging technologies such as targeted protein degradation will significantly advance progress in this field. Protein degradation modulates protein levels by harnessing the cell's endogenous ubiquitin-proteasome system to degrade proteins of interest (POI), differing from traditional drugs that achieve therapeutic effects by inhibiting target protein functions. To accelerate the discovery of protein degradation molecules, HitGen Inc employs DNA-encoded compound library (DEL) technology to identify small molecule ligands with affinity, where DNA tags provide connection sites for linker attachment. HitGen Inc's Targeted Protein Degradation Platform (TPDP), validated through multidisciplinary biochemical and biophysical experiments, supports innovative drug discovery programs leveraging protein degradation as a core regulatory mechanism. The TPDP encompasses the following capabilities: